Hepion Pharmaceuticals Inc (HEPA)

[Fress]

$2.15 last trade after hours.

"Nearly 45% of all deaths in the developed world are attributed to some type of chronic fibroproliferative disease. Therefore the demand for antifibrotic drugs that are both SAFE & EFFECTIVE is likely to be enormous."
-NIH

NASH 35 Billion dollar market today nearing 100 Billion in the next 7 years. NO approved NASH drugs to date.

In just 28 days at the low dose, HEPA CRV431 results were as good as what Madrigal's P3 lead NASH drug took 12 weeks to accomplish.


HEPA Tackling Chronic Liver Disease - CRV431 Mechanism of Action.

HEPA With a NASH & the dozen other possible applications HEPA is looking at this can be trading multiples from currents levels.

Former Novo Nordisk Executive, Dr. Todd M. Hobbs, Joins Hepion Pharmaceuticals as Chief Medical Officer
https://www.biospace.com/article/releases/former-novo-nordisk-executive-dr-todd-m-hobbs-joins-hepion-pharmaceuticals-as-chief-medical-officer/

Hobbs didn't leave 190 Billion dollar company as one of their highest level execs to become CMO for tiny HEPA unless its for a big reason.


HEPA June 2021 HEPA Biz Presentation.
https://hepionpharma.com/wp-content/uploads/2021/06/Corporate-deck-June-2021-FINAL.pdf



Nash Peers in Phase 2 & 3 Trials by companies in the NASH space:
AKRO Akero Therapeutics 1.1 Billion Marketcap 240 Million in cash.
MDGL Madrigal Pharmaceutical 1.7 Billion Marketcap 300 Million in cash.
HEPA Hepion Pharmaceuticals 160 Million market cap 120 million in cash.

Most importantly there are 76 million HEPA shares outstanding. >95% institutional ownership.

No filings were submitted for ~70% of the 64 million shares bought at the November and February offerings, meaning the vast majority was concealed.

Before institutions bought 64 million shares at those offerings, there were 12 million shares out, with 3 million in the public float. So, direct holders had ~9 million shares of that, and tutes got 64 million shares at the offerings, which possibly left ~3 million shares for retail then. Also the chart just reversed. Company has 120 million in the bank burning under 5 million a quarter!

- Partnership / Mix CRV-431 with others pills / New molecule
- News Positive effects of CRV-431
Potential buyout suitors could be Novo Nordisk or Gilead
Hepa other possible BLOCKBUSTER indications:
Diabetes.
Hepatitis
HVB.
Alzheimer’s
NASH Nash drug CRV431( 500 Million patients in the world )
Covid.
Endometrial Carcinoma.


HEPA AI Powr platform to save time and money on clinical trials.
https://hepionpharma.com/ai-powr/


$HEPA